易明医药
(002826)
| 流通市值：33.49亿 | | | 总市值：36.63亿 |
| 流通股本：1.74亿 | | | 总股本：1.91亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 148,531,481.16 | 651,883,906.6 | 512,843,177.87 | 351,984,809.03 |
| 营业收入 | 148,531,481.16 | 651,883,906.6 | 512,843,177.87 | 351,984,809.03 |
| 二、营业总成本 | 137,710,650.37 | 622,489,893.1 | 488,755,312.52 | 331,773,900.58 |
| 营业成本 | 29,899,682.84 | 205,252,937.23 | 168,993,735.65 | 118,686,529.49 |
| 税金及附加 | 2,984,869.04 | 12,274,464.69 | 9,002,043.52 | 6,569,275.91 |
| 销售费用 | 87,778,691.76 | 341,227,732.29 | 258,307,479.95 | 171,065,324.31 |
| 管理费用 | 15,816,207.02 | 49,417,529.07 | 41,309,596.7 | 28,285,424.72 |
| 研发费用 | 1,197,352.52 | 15,482,858.58 | 12,082,095.39 | 7,974,813.16 |
| 财务费用 | 33,847.19 | -1,165,628.76 | -939,638.69 | -807,467.01 |
| 其中:利息费用 | 200,738.92 | 445,889.7 | 294,657.13 | 181,080.57 |
| 其中:利息收入 | 178,542.83 | 1,682,915.88 | 1,288,378.39 | 1,026,650.41 |
| 加:投资收益 | 147,791.65 | 3,513,562.9 | 800,251.38 | 832,667.23 |
| 资产处置收益 | -231,263.9 | -44,949.62 | -37,811.88 | 23,994.09 |
| 资产减值损失(新) | -2,893.59 | -291,066.14 | - | 812.52 |
| 信用减值损失(新) | 119,817.11 | -902,425.79 | -3,011,381.33 | -3,848,909.56 |
| 其他收益 | 10,275,514.1 | 29,832,030.2 | 29,384,456.29 | 29,183,090.83 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 21,129,796.16 | 61,501,165.05 | 51,223,379.81 | 46,402,563.56 |
| 加:营业外收入 | 25,238.3 | 911,853.08 | 301,166.23 | 242,769.78 |
| 减:营业外支出 | 148,801.91 | 2,037,442.8 | 886,320.87 | 413,699.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 21,006,232.55 | 60,375,575.33 | 50,638,225.17 | 46,231,633.78 |
| 减:所得税费用 | 2,077,675.98 | 12,915,577.3 | 8,017,587.26 | 6,312,213.41 |
| 六、净利润 | 18,928,556.57 | 47,459,998.03 | 42,620,637.91 | 39,919,420.37 |
| 持续经营净利润 | 18,928,556.57 | 47,459,998.03 | 42,620,637.91 | 39,919,420.37 |
| 归属于母公司股东的净利润 | 18,793,851.93 | 45,928,802.86 | 41,819,396 | 39,646,165.15 |
| 少数股东损益 | 134,704.64 | 1,531,195.17 | 801,241.91 | 273,255.22 |
| (一)基本每股收益 | 0.1 | 0.25 | 0.22 | 0.21 |
| (二)稀释每股收益 | 0.1 | 0.25 | 0.22 | 0.21 |
| 八、其他综合收益 | -66,176.78 | 672,703.34 | -545,789.14 | 260,935.88 |
| 归属于母公司股东的其他综合收益 | -66,176.78 | 672,703.34 | -545,789.14 | 260,935.88 |
| 九、综合收益总额 | 18,862,379.79 | 48,132,701.37 | 42,074,848.77 | 40,180,356.25 |
| 归属于母公司股东的综合收益总额 | 18,727,675.15 | 46,601,506.2 | 41,273,606.86 | 39,907,101.03 |
| 归属于少数股东的综合收益总额 | 134,704.64 | 1,531,195.17 | 801,241.91 | 273,255.22 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-30 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |